Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| Country | Canada |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Joseph Oliveto |
Contact Details
Address: 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montreal, QC H4M 2X6 Canada | |
| Phone | 514 336 0444 |
| Website | milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Director |
| Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor and Member of Scientific Advisory Board |
| Jeffrey Nelson | Chief Operating Officer |
| Kim Fox | Vice President of Communications |
| Roshan Girglani | Vice President of Marketing |
| Jeff Moore | Vice President of Sales |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 424B5 | Filing |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |